Healthcare Companies Report Growth through FDA Approvals, Agreements and Announcements - Research Report on Johnson & Johnson,

   Healthcare Companies Report Growth through FDA Approvals, Agreements and
Announcements - Research Report on Johnson & Johnson, Stryker, Vertex, Fonar,
                                 and Nordion

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 28, 2013

NEW YORK, November 28, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Stryker Corp. (NYSE: SYK), Vertex Pharmaceuticals
Incorporated (NASDAQ: VRTX), Fonar Corp. (NASDAQ: FONR), and Nordion Inc.
(NYSE: NDZ). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On November 22, 2013, Janssen Therapeutics, a division of Janssen Products,
LP, which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson,
reported that the US Food and Drug Administration (FDA) has approved OLYSIO™
(simeprevir). According to the Company, OLYSIO™ works by blocking the viral
protease enzyme that enables the hepatitis C virus (HCV) to replicate in host
cells. Douglas Dieterich, M.D., Professor of Medicine in the Division of Liver
Diseases, Mount Sinai School of Medicine, and Clinical Trial Investigator for
OLYSIO^TM, stated, "Given the complexity of the condition, OLYSIO^TM was
studied in a number of different patient populations, including individuals
who have relapsed or failed to respond to previous treatments. The FDA
approval of OLYSIO^TM is an important milestone for people living with chronic
hepatitis C as it means that patients have a new treatment option with the
potential to cure this challenging disease." The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Stryker Corp. Research Report

On November 25, 2013, Stryker Corp.'s (Stryker) stock went up by 0.62% at
$74.74 per share. Over the past three trading days, the Company's stock
increased by 1.29%, compared to the Dow Jones Industrial Average which went up
by 1.08% over the same period. The Full Research Report on Stryker Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b34_SYK

--

Vertex Pharmaceuticals Incorporated Research Report

On November 20, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
that it has sold its royalty rights relating to INCIVO® (telaprevir) to
Janssen Pharmaceutica N.V. According to Vertex, pursuant to the agreement
Janssen will make a cash payment of $152 million to the Company by Q4 2013 and
will cease paying royalties to Vertex on INCIVO sales starting 2014.
Commenting on the release, Ian Smith, Executive Vice President and CFO of the
Company, stated, "The monetization of INCIVO royalties provides cash to
enhance our corporate financial position and continues to position us to
support our investment in cystic fibrosis and to advance other key
opportunities in our pipeline." Additionally, consequent to the amendment of
the companies' 2006 collaboration agreement to develop and commercialize
INCIVO in Europe and other regions, Janssen will have sole authority to
execute INCIVO marketing and promotion activities in these regions. The Full
Research Report on Vertex Pharmaceuticals Incorporated - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/e696_VRTX

--

Fonar Corp. Research Report

On November 25, 2013, Fonar Corp.'s (Fonar) stock went down by 9.35% as it
closed the day at $19.01 per share. However, over the previous three trading
day period, the Company's stock was up by 8.88%, compared to the Dow Jones
Industrial Average which went up by 1.08% during the same trading period. The
Full Research Report on Fonar Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/73cc_FONR

--

Nordion Inc. Research Report

On November 25, 2013, Nordion Inc.'s (Nordion) stock closed at $8.30 per
share, reflecting a decrease of 0.24%. Over the past three trading day period,
the Company's stock showed an increase of 0.24%, compared to the S&P 500 which
went up by 1.19% during the same period. The Full Research Report on Nordion
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c1d5_NDZ

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.